With a new online resource, Eisai is offering patients and caregivers some direction to help navigate a kidney cancer ...

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of ...

Combination cut risk of recurrence or death by 28% in patients at high risk of relapse ...

The combination of belzutifan plus lenvatinib significantly improved outcomes for patients with clear cell renal cell carcinoma who progressed following immunotherapy compared with cabozantinib ...

Belzutifan-lenvatinib slows progression versus cabozantinib with much longer response dura ...

The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...

At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...

Built on Insights from Patients and Caregivers, the New Website Curates Trusted Resources from Leading Organizations in Kidney Cancer NUTLEY, N.J., Feb. 26, 2026 /PRNewswire/ -- Eisai Inc. announced ...

Add Yahoo as a preferred source to see more of our stories on Google. Kidney cancer cases are projected to nearly double by 2050, but researchers say prevention and early detection can help curb the ...

Kidney cancer affects tens-of-thousands every year, but research and care advances are improving survival chances and quality of life for patients. Kidney cancer occurs more frequently than many ...

A 74-year-old man, diagnosed with advanced kidney cancer and facing an 80% damaged kidney, opted for natural treatment at ...

Kidney cancer is on the verge of becoming a far larger health problem than it currently is, with cases expected to nearly double by 2050 worldwide. That’s the bleak conclusion in a sweeping survey led ...